Athira is a clinical stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule, in later-stage clinical trials for Alzheimer's. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.Athira, headquartered in Seattle, is a clinical stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule, in later-stage clinical trials for Alzheimer's.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/04/20 | $85,000,000 | Series B |
Franklin Templeton Highside Capital Management Janus Henderson Investors LifeSci Venture Partners Logos Capital Perceptive Advisors  Rock Springs Capital RTW Investments Sofinnova Ventures Surveyor Capital Venrock Healthcare Partners Viking Global Investors | undisclosed |
